Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Multicentre, Open Study to Assess the Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients Previously Treated or Not by Somatostatin Analogues.

NCT00210457 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT00210457
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00210457 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Multicentre, Open Study to Assess the Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients Previously Treated or Not by Somatostatin Analogues.
Lead sponsor
Ipsen
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2000
Completion date
July 15, 2002
Enrollment
63 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

acromegaly